10 Roche Accutane Patient Registry Anticipated By Mid 2001 - FDA
Executive Summary
FDA anticipates Roche will have a mandatory registry in place for its acne drug Accutane by mid-2001, Office of Drug Evaluation V Deputy Director Jonca Bull, MD, testified during a Dec. 5 House Government Reform Committee hearing.
You may also be interested in...
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.
Jonca Bull Brings Clinical Experience To FDA Minority Health Office
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.
Accutane Generics Need Separate Risk Management Programs, Roche Says
FDA should require that generic isotretinoin applicants implement their own pregnancy prevention programs instead of incorporating the generics into Roche's Accutane risk management program, Roche argued in a Feb. 5 citizen petition